USA flag logo/image

An Official Website of the United States Government

CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / STTR
Agency Tracking Number:
R41AG042205
Solicitation Year:
2012
Solicitation Topic Code:
NIA
Solicitation Number:
PA11-097
Small Business Information
YUMA THERAPEUTICS CORPORATION
1770 Massachusetts Avenue, Suite 170 Cambridge, MA 02140-
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease
Agency: HHS
Contract: 1R41AG042205-01
Award Amount: $200,752.00
 

Abstract:

DESCRIPTION (provided by applicant): Research and Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neurodegenerative diseases. In this proposal the tau pathway is targeted through inhibition of the molecular chaperone Hsp90 as a promising new approach to affect the disease progression of AD. The goal of this grant is to optimize two structurally distinct scaffolds aided by in silico modeling and physical-chemical property predictions in order to generate novel brain permeable Hsp90 inhibitors as AD therapeutics. Subsequently, these compounds will be clinically developed for the treatment of AD using CSF biomarkers, as well as improved cognition,for in vivo efficacy determinations. PUBLIC HEALTH RELEVANCE: Research and Related Other Project Information Item 8. Project Narrative This research is focused on identifying potential drug candidates to treat Alzheimer's disease (AD) and in thisway it addresses NIA's priorities to support research on health and disease in the aged. Furthermore, this project targets the tau pathway as a promising new approach to affect the disease progression of AD.

Principal Investigator:

Yukari Perrella
617-953-4618
yukari.y.perrella@yumatherapeutics.com

Business Contact:

Yukari Perrella
617-953-4618
yukari.y.perrella@yumatherapeutics.com
Small Business Information at Submission:

YUMA THERAPEUTICS CORPORATION
1770 Massachusetts Avenue, Suite 170 Cambridge, MA 02140-

EIN/Tax ID: 190050648
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
BRIGHAM AND WOMEN'S HOSPITAL
BRIGHAM AND WOMEN'S HOSPITAL
RESEARCH ADMINISTRATION 75 FRANCIS ST
BOSTON, MA 02115-
Contact: